Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
Authors
Yaoyue Zhang
Yue Shi (ORCID: https://orcid.org/0000-0002-7439-7042)
Yushan Jia
Zhikuan Wang (ORCID: https://orcid.org/0000-0002-7025-735X)
Haiyan Si (ORCID: https://orcid.org/0000-0003-2883-7526)
Nan Zhang (ORCID: https://orcid.org/0009-0005-1392-8689)
Fangfang Liu (ORCID: https://orcid.org/0000-0001-9792-1911)
Quanli Han (ORCID: https://orcid.org/0000-0002-7389-934X)
Guanghai Dai (ORCID: https://orcid.org/0000-0002-7339-3840)
Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
Yaoyue Zhang, Yue Shi, Yushan Jia, Zhikuan Wang et al.
Journal
BMC Cancer
Topics
Colorectal Cancer Treatments and Studies
article
Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer